BsAb Intelligence · Research Tools · Discovery Services

Understand the Pair. Build the Experiment.

Intelligence, research tools and discovery services for bispecific antibody development.

Explore Target Pairs → Explore Research Tools → Discuss a BsAb Project

PD-1 · PD-L1 · VEGF-A · DLL3 · CD3 · EGFR · LGR5 · MET · Dual Binding · SPR · BLI · TCE · BsAb · PD-1 · PD-L1 · VEGF-A · DLL3 · CD3 · EGFR · LGR5 · MET · Dual Binding · SPR · BLI · TCE · BsAb ·

Explore

Six doors · one evidence standard

Target Pairs5 Golden Pairs · Opportunity Scores IntelligenceEvent intelligence & weekly briefs Research ToolsQC-graded proteins & matched pairs ServicesDiscovery workflows, SOW-based ResourcesGuides, protocols & landscapes Market ReportBsAb-MR-2026Q3 · 12 chapters

What's New

auto-driven by review-log · zero manual curation

Pair Landscape2026-09-03

EGFR × MET Target Pair Landscape — Approved Reference, Multi-Generational Pipeline

Read →Pair Landscape2026-09-03

EGFR × LGR5 Target Pair Landscape — An Emerging Pair With a Real Reagent Gap

Read →Pair Landscape2026-09-03

DLL3 × CD3 Target Pair Landscape — The TCE Benchmark Pair

Read →

Golden Target Pairs

5 pairs · 8 core targets · Grade A/B evidence

01Checkpoint × Angiogenesis

PD-1 × VEGF-A

Combines PD-1 checkpoint blockade with VEGF-A anti-angiogenesis in one molecule; flagship pair with ivonescima…

Explore Pair →

02Checkpoint × Angiogenesis

PD-L1 × VEGF-A

Axis clinically validated (atezolizumab+bevacizumab FDA-approved 1L HCC 2020) but no PD-L1×VEGF bispecific app…

Explore Pair →

03Tumor Target × T-cell Engager

DLL3 × CD3

The reference T-cell engager pair: DLL3 is a tumor-selective Notch ligand enriched in SCLC/neuroendocrine tumo…

Explore Pair →

04Dual Tumor Target

EGFR × LGR5

Emerging pair combining EGFR (mature, validated) with LGR5 (Wnt/stemness, tumor-initiating cell marker) to tar…

Explore Pair →

05Dual Receptor Targeting

EGFR × MET

Mature dual-receptor pair with an approved reference asset: amivantamab (EGFR×MET, 4 FDA NSCLC indication bull…

Explore Pair →

5Golden Pairs

8Core Targets

26Evidence Pages

538Trials in Census

Technical Notes

Resources · evergreen content

01Experimental Design: CD16a 158V vs 158F Side-by-Side ComparisonTechnical Notes
02How to Select the Right CD16a (FcγRIIIa) Variant for FcγR Binding StudiesTechnical Notes
03CD47 / SIRPα Blocking Assay Design: Avoiding the Pitfalls That Invalidate Your DataTechnical Notes
04Choosing CD3 Protein Formats for T-Cell Engager DevelopmentTechnical Notes
05CHO vs HEK293 for Early BsAb ExpressionTechnical Notes
06How to Design a DLL3 × CD3 Functional Screening WorkflowTechnical Notes
07How to Validate Dual Binding for a Bispecific AntibodyTechnical Notes
08Human vs Cynomolgus Antigen SelectionTechnical Notes
09How to Design an FcRn SPR Assay for pH-Dependent Antibody Half-Life EvaluationTechnical Notes
10Step-by-Step: FcRn SPR Protocol with pH 6.0 / 7.4 Dual-Buffer SwitchTechnical Notes
11IL-15 for NK Cell Expansion: Concentrations, Combinations, and Common FailuresTechnical Notes
12PD-1 × VEGF-A Target Pair Landscape — What's Happening and Why It MattersTechnical Notes
13PD-L1 × VEGF-A Target Pair Landscape — Axis Validated, Format UnapprovedTechnical Notes
14DLL3 × CD3 Target Pair Landscape — The TCE Benchmark PairTechnical Notes
15EGFR × LGR5 Target Pair Landscape — An Emerging Pair With a Real Reagent GapTechnical Notes
16EGFR × MET Target Pair Landscape — Approved Reference, Multi-Generational PipelineTechnical Notes
17TIGIT / CD155 Matched Pair: Workflow and Optimization for BLI and SPRTechnical Notes

Topics

Resources · evergreen content

Protocols

Resources · evergreen content

01Protocol: CD16a SPR KD Measurement — 158V vs 158F Side by SideProtocols
02Protocol: CD47–SIRPα SPR Binding & Antibody BlockingProtocols
03Protocol: IL-15 NK Expansion (PBMC-based, Research Grade)Protocols
04Protocol: TIGIT–CD155 BLI Binding & CompetitionProtocols